In a research report published Friday, Wedbush analyst David Nierengarten maintained a Neutral rating on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) with a $2.
Chicago IL / Research Report Wire / February 27th, 2015 / Institutional Analyst Inc.(IA) announced today it released the its Top 20 Biotech …
Roth Capital analyst Joseph Pantginis upgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from Hold to Buy, and raised his price target to $4.30 (from $2.
In a research report released earlier today, Cantor analyst Mara Goldstein upgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from Hold to Buy and doubled her …
Roth Capital analyst Joseph Pantginis reiterated a Neutral rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) with a $2.30 price target, as the company presented data from its ongoing …
In a research report sent to investors, Cowen analyst Eric Schmidt maintained an Outperform rating on Sunesis Pharmaceuticals (NASDAQ:SNSS). No price target was provided.
In a research note published this morning, Cantor Fitzgerald analyst Mara Goldstein maintained a Hold rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) with a $2 …
In a research report sent to investors today, Roth Capital analyst Joseph Pantginis maintained a Neutral rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) with a …
In a research report issued October 6 to investors, Wedbush analyst David Nierengarten reiterated a Neutral rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) and significantly reduced his …
In a research report issued today, Roth Capital analyst Joseph Pantginis downgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a Buy to a Neutral rating and lowered …
